213 related articles for article (PubMed ID: 35427142)
21. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.
Anreddy N; Patel A; Zhang YK; Wang YJ; Shukla S; Kathawala RJ; Kumar P; Gupta P; Ambudkar SV; Wurpel JN; Chen ZS; Guo H
Oncotarget; 2015 Nov; 6(36):39276-91. PubMed ID: 26515463
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.
Kang L; Jiang D; Ehlerding EB; Barnhart TE; Ni D; Engle JW; Wang R; Huang P; Xu X; Cai W
Mol Pharm; 2018 Apr; 15(4):1627-1634. PubMed ID: 29537283
[TBL] [Abstract][Full Text] [Related]
23. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
24. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
Kalalinia F; Elahian F; Behravan J
J Cancer Res Clin Oncol; 2011 Feb; 137(2):321-30. PubMed ID: 20422426
[TBL] [Abstract][Full Text] [Related]
25. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
26. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
Su Y; Lee SH; Sinko PJ
Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
[TBL] [Abstract][Full Text] [Related]
28. MiR-548 K regulatory effect on the ABCG2 gene expression in MDR breast cancer cells.
Saberiyan M; Ghasemi Z; Yaghoobi H
Cancer Rep (Hoboken); 2023 Jun; 6(6):e1816. PubMed ID: 37166017
[TBL] [Abstract][Full Text] [Related]
29. Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.
Sinha BK; Perera L; Cannon RE
Biomed Pharmacother; 2019 Dec; 120():109468. PubMed ID: 31605952
[TBL] [Abstract][Full Text] [Related]
30. Decreased NMIIA heavy chain phosphorylation at S1943 promotes mitoxantrone resistance by upregulating BCRP and N-cadherin expression in breast cancer cells.
Li K; Li T; Niu Y; Gao Y; Shi Y; He Y; Zhang X; Wang Y; Cao J; Hu X; Chen M; Shi R
Biochem Cell Biol; 2024 Jun; 102(3):213-225. PubMed ID: 38190650
[TBL] [Abstract][Full Text] [Related]
31. Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.
Takara K; Yamamoto K; Matsubara M; Minegaki T; Takahashi M; Yokoyama T; Okumura K
PLoS One; 2012; 7(2):e30697. PubMed ID: 22355323
[TBL] [Abstract][Full Text] [Related]
32. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
33. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
Zhang S; Yang X; Morris ME
Mol Pharmacol; 2004 May; 65(5):1208-16. PubMed ID: 15102949
[TBL] [Abstract][Full Text] [Related]
34. Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance.
Ding R; Shi J; Pabon K; Scotto KW
Mol Pharmacol; 2012 Mar; 81(3):328-37. PubMed ID: 22113078
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and biological evaluation of phenylurea indole derivatives as ABCG2 inhibitors.
Ye GJ; Cai CY; Dong XD; Wu ZX; Teng QX; Wang JQ; Chen ZS; Wang B
Bioorg Chem; 2023 Jun; 135():106481. PubMed ID: 36966672
[TBL] [Abstract][Full Text] [Related]
36. Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
Cai CY; Zhai H; Lei ZN; Tan CP; Chen BL; Du ZY; Wang JQ; Zhang YK; Wang YJ; Gupta P; Wang B; Chen ZS
Eur J Med Chem; 2019 Oct; 179():849-862. PubMed ID: 31302589
[TBL] [Abstract][Full Text] [Related]
37. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
38. Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells.
Ghalehno AD; Abdi H; Boustan A; Jamialahmadi K; Mosaffa F
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3723-3732. PubMed ID: 37310508
[TBL] [Abstract][Full Text] [Related]
39. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
40. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]